Transcription of A Phase II Randomized, Double-Blinded, Controlled Study in ...
{{id}} {{{paragraph}}}
A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without MF59 AdjuvantDMID Protocol Number: 13-0032 DMID Funding Mechanism:Vaccine Treatment and Evaluation UnitsPharmaceutical Support:sanofi pasteurNovartis Vaccines and DiagnosticsIND Sponsor:Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of HealthLead Principal Investigator:Mark J. Mulligan, MD, FIDSADMID Clinical Project Manager: Wendy L.
A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus …
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Grading, Training, Policy, IATA, IATA Training and Qualification Initiative ITQI, Training Policy, International Air Transport Association, National Tourism Sector Strategy, IATA International Air Transport Association, Compliance Audit Handbook, 2B Safety and Effectiveness Study of, Lithium-Ion Batteries Hazard and Use Assessment